Can Gadoxetate-Enhanced MRI Predict Outcomes in PSC?

Managing primary sclerosing cholangitis (PSC) represents a major clinical challenge for hepatologists worldwide, including in India. Predicting which patients will progress to liver failure, require transplantation, or suffer from severe complications remains difficult. Specifically, traditional clinical scores often fall short of providing timely, individualized risk assessment. To address this gap, researchers have investigated the clinical utility of gadoxetate-enhanced MRI in PSC. This advanced imaging modality provides functional details that could greatly improve prognostic accuracy.

The Prognostic Value of gadoxetate-enhanced MRI in PSC

A landmark retrospective study evaluated 73 patients with primary sclerosing cholangitis who underwent liver imaging. Researchers aimed to determine if functional biliary and hepatic data from contrast-enhanced scans could predict outcomes. Consequently, four independent radiologists analyzed the qualitative and quantitative imaging findings. They compared these findings with standard radiological and clinical scoring models over a two-year follow-up period. Ultimately, this comprehensive comparison revealed valuable insights into disease progression.

Predicting Adverse Events with Duct Enhancement

During the two-year observation period, several patients experienced significant clinical deterioration. Specifically, twenty-six patients suffered from adverse events, including six deaths. On multivariate statistical analysis, the Mayo Risk Score emerged as a strong clinical predictor. In addition, the relative enhancement of the proximal extrahepatic bile ducts (REPD) was highly significant. An REPD threshold of less than 4.64 predicted adverse outcomes with 70% sensitivity and 63% specificity. Therefore, measuring bile duct enhancement provides clinicians with a quantifiable, objective marker for patient risk.

ANALI Scores and Transplant Risk Prediction

While REPD successfully predicted general adverse events, predicting liver transplantation required different tools. Remarkably, the ANALI non-gadolinium score was the only variable that significantly predicted the need for liver transplantation. Specifically, patients with an ANALI score of greater than 3 faced a substantially higher risk. This specific cutoff achieved a high sensitivity of 87.5% alongside a specificity of 74.2%. Thus, clinicians should combine clinical risk models, ANALI scores, and REPD values for comprehensive patient stratification. In conclusion, integrating these imaging biomarkers into routine hepatology practice in India can optimize the management of this complex disease.

Frequently Asked Questions

Q1: What is the significance of REPD in patients with primary sclerosing cholangitis?

Relative enhancement of the proximal extrahepatic bile ducts (REPD) serves as a functional imaging marker. Specifically, an REPD value of less than 4.64 helps predict adverse clinical events within two years with high sensitivity and specificity.

Q2: How does the ANALI non-gadolinium score help in managing PSC?

The ANALI non-gadolinium score serves as an excellent predictor for the need for liver transplantation. Furthermore, an ANALI score of greater than 3 identifies high-risk patients who might require transplant planning.

Q3: Can clinical scores like the Mayo Risk Score be replaced by MRI findings?

Clinical scores remain highly valuable and should not be replaced. Instead, clinicians should combine clinical risk scores with functional MRI metrics like REPD to establish a more accurate, multi-dimensional prognosis.

References

1. Sandrasegaran K et al. Do hepatic and biliary functional data from gadoxetate-enhanced MRI add value in predicting outcomes in primary sclerosing cholangitis (PSC)? Eur Radiol. 2026 Jun 27. doi: 10.1007/s00330-026-12710-5. PMID: 42363965.
2. Nilsson H, Blomqvist L, Douglas L, Nordell A, Jacobsson H, Hagen K, Bergquist A, Jonas E. Dynamic gadoxetate-enhanced MRI for the assessment of total and segmental liver function and volume in primary sclerosing cholangitis. J Magn Reson Imaging. 2014;39(4):879-86. doi: 10.1002/jmri.24250.
3. Schulze J et al. An imaging biomarker for assessing hepatic function in patients with primary sclerosing cholangitis. Clin Gastroenterol Hepatol. 2019;17(1):192-9. doi: 10.1016/j.cgh.2018.06.015.